{"text": ["3", "Large-Cap", "Stocks", "to", "Buy", "and", "Hold", "to", "Start", "Q2"], "created_at": "2021-04-07 23:53:11"}
{"text": ["Pfizer\u2019s", "Xeljanz", "Faces", "Canadian", "Review", "Amid", "More", "Scrutiny", "of", "JAK", "Inhibitors"], "created_at": "2021-04-07 14:14:00"}
{"text": ["Barron\u2019s", "Stock", "Screen:", "The", "5", "\u2018Dividend", "Aristocrats\u2019", "With", "the", "Fastest-Growing", "Payouts"], "created_at": "2021-04-07 13:10:00"}
{"text": ["AbbVie", "Submits", "Regulatory", "Applications", "for", "SKYRIZI\u00ae", "(risankizumab)", "in", "Psoriatic", "Arthritis", "to", "FDA", "and", "EMA"], "created_at": "2021-04-07 13:00:00"}
{"text": ["AbbVie", "to", "Present", "Data", "Across", "its", "Robust", "Neuroscience", "Portfolio", "at", "the", "2021", "American", "Academy", "of", "Neurology", "(AAN)", "Annual", "Meeting"], "created_at": "2021-04-07 12:00:00"}
{"text": ["Not", "All", "Dividend", "Aristocrats", "Are", "the", "Same.", "Here", "Are", "5", "With", "Fast-Growing", "Payouts"], "created_at": "2021-04-07 10:00:00"}
